Emerging Treatment Options for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
Hannah Khan,Aamir A Aziz,Humza Sulahria,Huma Khan,Abrahim Ahmed,Netan Choudhry,Raja Narayanan,Carl Danzig,Arshad M Khanani
DOI: https://doi.org/10.2147/OPTH.S367089
2023-01-23
Clinical Ophthalmology
Abstract:Hannah Khan, 1 Aamir A Aziz, 1 Humza Sulahria, 2 Huma Khan, 2 Abrahim Ahmed, 3 Netan Choudhry, 4– 7 Raja Narayanan, 8, 9 Carl Danzig, 10 Arshad M Khanani 1, 2 1 University of Nevada, Reno School of Medicine, Reno, NV, USA; 2 Sierra Eye Associates, Reno, NV, USA; 3 Morsani College of Medicine, University of South Florida, Tampa, FL, USA; 4 Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada; 5 Vitreous Retina Macula Specialists of Toronto, Etobicoke, Ontario, Canada; 6 Cleveland Clinic Canada, Toronto, Ontario, Canada; 7 Octane Imaging Lab, Toronto, Ontario, Canada; 8 Anant Bajaj Retina Institute, LV Prasad Eye Institute, Hyderabad, Telangana, India; 9 Indian Health Outcomes, Public Health and Economics Research Centre (IHOPE), Hyderabad, Telangana, India; 10 Rand Eye Institute, Deerfield Beach, FL, USA Correspondence: Arshad M Khanani, Sierra Eye Associates, 950 Ryland Street, Reno, NV, USA, Tel +1 775 329-0286, Fax +1 775 329-0849, Email Age-related macular degeneration (AMD) is characterized as a chronic, multifactorial disease and is the leading cause of irreversible blindness. Advanced AMD is classified as neovascular (wet) AMD and non-neovascular (dry) AMD. Dry AMD can progress to a more advanced form that manifests as geographic atrophy (GA), which significantly threatens vision, leading to progressive and irreversible loss of visual function. There are currently no approved therapeutics commercially available for GA patients. However, data from various clinical trials have demonstrated favorable results with significant reduction in GA lesion growth. Approaches to GA treatment vary from complement inhibitors to ocular gene therapy, some of which may delay disease progression, while others may reverse the disease. This review furthers the understanding of the pathophysiology of GA, as well as current clinical trial data on investigational therapeutics. Keywords: complement system, gene therapy, neuroprotective agents, personalized treatment, anti-inflammatory agents, intravitreal injection Age-related macular degeneration (AMD) is a multifactorial, degenerative disease associated with progressive vision loss, and is more common in developed nations but is prevalent in all countries. 1 AMD is categorized into two major subtypes: non-neovascular (dry or non-exudative) and neovascular (wet or exudative; nAMD) form. 2 Macular neovascularization (MNV) in the retina or choroid is a characteristic of nAMD with associated acute vision loss. Anti-vascular endothelial growth factor (anti-VEGF) treatment has proven efficacious in nAMD patients as it targets neovascularization and treats associated intra- (IRF) and subretinal fluid (SRF). If untreated, MNV can induce leakage of fluid, lipids, and blood into the outer retina, resulting in irreversible vision loss. Dry AMD can progress to an advanced degenerative stage manifesting as geographic atrophy (GA), characterized by irreversible vision loss due to loss of retinal pigment epithelium (RPE), photoreceptors and choriocapillaris in the macula. 3 Visual acuity can remain intact with spared foveal involvement in some GA patients. Enlargement of GA is associated with furthering disease progression, ultimately leading to irreversible vision morbidity. 4 Nonmodifiable risk factors, including genetics and age, and modifiable risk factors such as smoking status, and comorbidities such as hypertension, are inherently associated with GA progression. 5 Studies have indicated ocular benefits and delayed disease progression in conjunction with a healthy lifestyle. 6 Currently, there are no therapeutics approved for GA; however, numerous clinical trials are underway investigating potential therapeutics for reduction in GA lesion growth. In this review, we focus on the pathophysiology of GA, as well as current investigational therapeutics for the disease. Publications regarding GA were identified via a systematic literature search on the PubMed/MEDLINE database and ClinicalTrials.gov website. The term "geographic atrophy" was used in conjunction with "treatments", "diagnosis", and "management." In addition, literature cited in the reference lists of identified GA publications were also utilized. Current and recent therapeutics were compiled and summarized for this review. The complement system interacts with various proteins to result in a humoral immune response and has three pathways: classical, alternative, or mannose-binding lectin. 7 The classical pathway activates via antibody-antigen recognition, and the mannose-binding lectin pathway activ -Abstract Truncated-